Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for patent litigation
European Patent Litigation Certificate returns to train tomorrow's patent litigators European Patent Litigation Certificate returns to train tomorrow's patent litigators Reviewed by Eleonora Rosati on Thursday, July 16, 2026 Rating: 5
Patent Litigation Europe Summit (formerly Pharma & Biotech Patent Litigation) returns to Amsterdam with IPKat readers' discount Patent Litigation Europe Summit (formerly Pharma & Biotech Patent Litigation) returns to Amsterdam with IPKat readers' discount Reviewed by Eleonora Rosati on Tuesday, September 30, 2025 Rating: 5
Keeping up with Belgian patent litigation: Year case law review 2024 and early 2025 Keeping up with Belgian patent litigation: Year case law review 2024 and early 2025 Reviewed by Annsley Merelle Ward on Thursday, September 11, 2025 Rating: 5
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Asude Sena Moya on Wednesday, June 18, 2025 Rating: 5
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Asude Sena Moya on Friday, May 30, 2025 Rating: 5
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Asude Sena Moya on Wednesday, May 14, 2025 Rating: 5
UK court reaffirms its stringent plausibility standard in AstraZeneca despite G 2/21 UK court reaffirms its stringent plausibility standard in AstraZeneca despite G 2/21 Reviewed by Annsley Merelle Ward on Friday, May 09, 2025 Rating: 5
ERA IP-focused events and courses return with 25% discount for IPKat readers ERA IP-focused events and courses return with 25% discount for IPKat readers Reviewed by Eleonora Rosati on Monday, April 22, 2024 Rating: 5
Netherlands calling with a 10% discount on C5's Pharma & Biotech Patent Litigation Conference Netherlands calling with a 10% discount on C5's Pharma & Biotech Patent Litigation Conference Reviewed by Annsley Merelle Ward on Friday, May 12, 2023 Rating: 5
WIPO publishes Guide to Patent Case Management for Judges WIPO publishes Guide to Patent Case Management for Judges Reviewed by Annsley Merelle Ward on Monday, April 24, 2023 Rating: 5
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Alexandre Miura on Wednesday, April 20, 2022 Rating: 5
No "German injunction gap" expedition in Abbott v Dexcom global diabetes battle, as Mr Justice Mellor expresses "some regret" No "German injunction gap" expedition in Abbott v Dexcom global diabetes battle, as Mr Justice Mellor expresses "some regret" Reviewed by Annsley Merelle Ward on Sunday, September 12, 2021 Rating: 5
[GuestPost] Opinion: Patent trolling threatens the market of taxi aggregators in Kazakhstan [GuestPost] Opinion: Patent trolling threatens the market of taxi aggregators in Kazakhstan Reviewed by Merpel McKitten on Monday, August 16, 2021 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.